Research Article

Factor V Leiden G1691A and Prothrombin G20210A mutations are associated with repeated spontaneous miscarriage in Northern area of Saudi Arabia

Received: September 29, 2017
Accepted: October 17, 2017
Published: October 21, 2017
Genet.Mol.Res. 16(4): gmr16039810
DOI: 10.4238/gmr16039810

Abstract

Maternally inherited thrombophilia could be one of the causes of recurrent spontaneous miscarriage (RSM). We aimed to investigate the frequency of three thrombotic gene variants; factor V Leiden (FVL; G1691A), prothrombin (PTH; G20210A), and methylenetetrahydrofolate reductase (MTHFR; C677T) in Saudi patients diagnosed with RSM. A case control study was conducted on 96 RSM patients and 96 age-matched controls. Genotyping was based on polymerase chain reaction followed by hybridization with variant-specific oligonucleotide probes using FV-PTH-MTHFR Strip Assay. There was a significantly higher frequency of the AA genotype of FVL in the RSM group when compared to controls (P <0.001, OR (95% CI) = 15.7 (3.6-68.5). For the PTH G20210A mutation, the heterozygous genotype (GA) showed significantly higher frequency in patient group than control group (P < 0.0001, OR (95% CI) = 3.8 (2.05-6.9). For the MTHFR C677T mutation, there was no significant difference in the distribution of genotypes and alleles among the patients and controls. There was a significant association between the combined genotypes; FVL AA, PTH GA, and MTHFR CC as well as FVL GA, PTH GA, and MTHFR CT and patients group when compared to the control group. The FVL and PTH variants could be helpful in identifying RSM risk among Saudi women in the Northern area of Saudi Arabia. The combination of a panel of variants may be more conclusive in prediction of the disease risk compared to the small effect of individual mutation

Introduction

Recurrent spontaneous miscarriage (RSM) is defined as ≥ 3 spontaneous successive early (before the 12th gestational week) miscarriages (Hossain et al., 2013), although previous studies considered it as two or more spontaneous abortions (Branch et al., 2010).

RSM is the most common complication of pregnancy in Saudi Female. Spontaneously aborted women represent about 18% of all clinically recognized pregnancies (Gawish and Al-Khamees, 2013). Although some known disorders in reproductive, endocrine and immunological systems as well as some infectious diseases and chromosomal aberrations were implicated in some cases (Teremmahi et al., 2013), more than 50 % of cases remain unexplained. When the aforementioned disorders are excluded, thrombophilia was speculated as possible cause of RSM (Martínez-Zamora et al., 2012). This latter condition is a status in which hypercoagulability is prominent, which may be acquired or inherited (Yokuş et al., 2010).

Hereditary thrombophilia may cause infarcts secondary to placental vascular micro-thrombosis that result in low placental perfusion and eventually recurrent miscarriages and intrauterine fetal death (Carrington et al., 2005). Most women with RSM, placental thrombosis may be the final common pathophysiological event (Kasparova and Fait, 2009).

Cao et al. (2013) have suggested that mutations of Factor V Leiden (FVL), prothrombin (PTH) and methylene tetrahydrofolate reductase (MTHFR) genes are the most common thrombogenic mutations that can cause inherited thrombophilia.

FVL mutation involves replacement of guanine by adenine (factor V Arg534Gln or factor V Leiden) (G>A) at the nucleotide 1691 gene position in exon 10 (Table 1), leads to resistance of factor V to the cleavage effect of activated protein C (APC) (McNamee et al., 2012). Meanwhile, PTH gene mutation resulted in a genetic variant in the 3`UTR (untranslated region) at position 20210 caused by substitution of adenine for guanine (Table 1), leading to hyper-prothrombinemia and increased thrombin generation (Castoldi et al., 2007).

Gene (ID) SNP ID Chromosome CDS Protein Function Poly Phen annotation (score)
No Position Position Allele change Position Residue change
FVL  (2153) Rs6025 1 (exon 10) 169549811 minus 1601 CGA Þ CAA 534 R[Arg] Þ Q[Gln] Missense Probably damaging (0.984)
PTH  (2147) Rs1799963 11 (3'UTR) 46739505 plus *97G>A 20210G>A NA NA 3 prime UTR variant NA
MTHFR (4524)  Rs1801133 1 (exon 5) 11796321 minus 667 GCC Þ GTC 222 A[Ala] ⇒ V[Val] Missense Probably damaging (0.996)

Table 1: General characteristics of the studied single nucleotide polymorphisms.

Another common mutation is MTHFR in which there is a substitution at position 677 of T instead of C (Table 1); leading to a reduced enzyme activity and subsequent hyperhomocysteinemia in homozygous cases that could predispose to thrombosis and RSM (Leclerc et al., 2013)

As there are no previous studies of the prevalence of the aforementioned mutations among Saudi women residents in the Northern Border area (NBA) of Saudi Arabia, this preliminary study aimed to detect the frequencies of these mutations in a group of Saudi females presented with unexplained RSM and to correlate these frequencies, with the available clinical and laboratory data of the patients.

This could help in refining the risk prevention and highlighting the importance of thromboprophylaxis in an attempt to improve the outcome of pregnancy in inherited thrombophilia affected women in the current area.

Material and Methods

Study Subjects

A case-control study was conducted on 96 patients with RSM (20-35 years) and 96 age-matched controls. A past history of ≥ 2 losses of pregnancy before the 20th gestational week has been confirmed for all patients who were enrolled from the Arar Obstetrics and Gynecology Hospital, Northern Border Area, Saudi Arabia. Other causes of RSM (e.g. endocrine, autoimmune, infectious, uterine factors, etc.) have been excluded.

Developmental or acquired reproductive system abnormalities, in addition, have been excluded by abdominal/pelvic ultrasound. Routine screening for hyperprolactinemia, thyroid dysfunction, diabetes, corpus luteum insufficiency and polycystic ovary syndrome have been done clinically and by laboratory testing for patient hormone profiles, including basal follicle stimulating hormone, luteinizing hormone, estradiol, luteal phase progesterone, thyroid stimulating hormone, free tri-iododthyronine and free tetra-iodothyronine. Patients with positive lupus anticoagulant and anti-phospholipid antibodies were also excluded.

Age-matched, healthy Northern Border University (NBU) employees’ females without a history of any pregnancy loss or chronic disease were allocated in the control group. Previous history of thrombosis has been excluded in both study groups. The study was conducted in accordance with the guidelines in the Declaration of Helsinki and was approved by the Medical and Bioethics local committee of NBU. All participants provided written informed consent to participate in the study after being informed with its purpose.

Blood Sample Collection

Genotyping

DNA extraction and amplification

DNA extraction from EDTA tubes of blood specimens has been done following the manufacturer’s instructions, using FV-PTH-MTHFR StripAssay kit (ViennaLab Labordiagnostika GmbH, Cat. No. 4-260, Vienna, Austria). All extracted DNA was kept frozen at -20°C until the time of amplification. FVL (G1691A), PTH (G20210A) and MTHFR (C677T) genes were amplified by polymerase chain reaction (PCR) and labeled with biotin simultaneously in a single (multiplex) amplification reaction. The PCR reaction mix for each amplified sample was containing Amplification Mix (15 μl), diluted Thermus Aquaticus DNA polymerase (1U), and DNA template (200 ng).

The PCR has been run on the thermocycler (C1000, BIO-RAD) following the manufacturer’s recommended program (i.e. 2 minutes initial DNA denaturation at 94˚C followed by incubation at 94˚C for 15 seconds, 58˚C for 30 seconds, and 72°C for 30 seconds; repeated for 30 cycles, then a final extension step for 3 minutes at 72˚C). The PCR products were stored at 2-8°C until the time of hybridization in the following day.

Amplification products reverse hybridization

Selective reverse hybridization for the amplified biotin-labelled products were done on the test strips provided with the kit. Each strip contains wild-type and mutant allele-specific oligonucleotide probes immobilized as an array of parallel lines (Figure 1). Briefly, each pre-amplified product (10 μl) mixed with the supplied hybridization buffer (1 ml) has been added to the test strip with orbital shaking for 30 min (at 45°C and 50 rpm) in a thermoshaker (Shy line shaker DTS-2), followed by three washing steps by the shaker at 45°C as recommended by the manufacturer.

Factor-Leiden-test-results

Figure 1: Examples of test results

Hybridized product identification

Mutant and wild type alleles that have been specifically bound to their probes on the strips, have been detected by color-developing enzymatic reaction. The procedure details have been illustrated in our previous work (Fawzy et al., 2017). Each strip has been evaluated by two independent authors and for each band, one of the following staining patterns should be obtained: normal genotype (positive wild type line and negative mutant line), heterozygous (positive for both wild type and mutant lines), or homozygous mutant (negative wild type line and positive mutant line) (Figure 1).

Statistical Analysis

Statistical Package for the Social Sciences (SPSS) for Windows, “version 16.0” has been used for data analysis. Mean ± standard deviation has been calculated for continuous variables, and frequencies (%) for categorical variables. The continuous variables comparison between cases and controls has been done by Student's t tests and Mann-Whitney (MW) U tests when appropriate and the categorical variables comparison has been done by applying Chi- Square tests or fisher exact test when appropriate. The genotypes and allele frequencies of the study mutations were calculated by counting. Hardy–Weinberg equilibriums (HWE) were assessed on a contingency table of observed and expected genotype frequencies using Chi-square (χ2) test. The association between case/control status and the thrombophilic mutations has been tested by logistic regression analysis with 95% confidence intervals (CI). Two tailed P values < 0.05 has been considered significant.

Results

Study subjects characteristics

The current case-control study was carried out on 96 women (37.7 ± 4.6 years) with a history of RSM and 96 healthy women (36.5 ± 5.8) as a normal control group who had at least two living children with a negative past history of abortion. Most of the patients had a history of RSM during the 1st trimester and a few of them presented by RSM during the 2nd trimester. Thirty-four patients (35.4 %) had a history of two consecutive miscarriages. Meanwhile, 37 patients (38.6 %) had 3 RSM and 25 patients (26.0 %) had 4 or more miscarriages. The baseline characteristics of the study participants have been summarized in Table 2.

Characteristics Controls (n = 96) Patients (n = 96) P value
Age, years 36.5 ± 5.8 37.7 ± 4.6 0.114
FH of abortion  
Negative 96 (100) 87 (90.6) 0.243
Positive 0 (0.0) 9 (9.4)  
Obstetric history      
Duration of marriage 12.0 ± 3.5 8.1 ± 4.3 <0.0001
No of living children 4.0 (3.0-5.0) 1.0 (1.0-4.0) <0.0001
No of abortions -- 3.0 (2.0-5.0)  
Drug history  
No drug intake -- 54 (56.3)  
Aspirin -- 27 (28.1)  
COCP -- 18 (18.8)  
Clexane -- 18 (18.8)  
Heparin -- 3 (3.1)  
Biochemical investigations  
PT 11.1 ± 0.5 11.2 ± 0.9 0.343
INR 1.0 ± 0.1 1.0 ± 0.1 1.0
PTT 31.3 ± 2.0 30.7 ± 5.1 0.285

Table 2: Baseline characteristics of the studied groups

Genotyping of The Study Population

Genotype distribution and allele frequencies of the studied mutations are illustrated in Table 3. The mutation distribution in controls was in Hardy–Weinberg equilibrium (P > 0.05) except FVL (G169A) genotype distribution due to the predominance of heterozygous genotype.

Polymorphism Controls
(n= 96)
Patients
(n = 96)
P value OR
(95 % CI)
FVL G169A (Leiden)
GG -- --    
GA 94 (97.9) 72 (75.0)  < 0.001 Ref.
15.7 (3.6-68.5)
AA 2 (2.1) 24 (25.0)
PTH G20210A        
GG 64 (66.7) 33 (34.4)   Ref.
GA 31 (32.3) 60 (62.5) < 0.0001 3.8 (2.05-6.9)
AA 1 (1.0) 3 (3.1) 0.134 5.8 (0.58-58.1)
MTHFR C677T        
CC 85 (88.5) 75 (78.1)   Ref.
2.2 (0.98-4.8)
CT 11 (11.5) 21 (21.9) 0.056
TT -- --    
Allele frequencies
FVL G169A (Leiden)        
G allele 94 (49.0) 72 (37.5) 0.024 Ref.
1.6 (1.06-2.4)
A allele 98 (51.0) 120 (62.5)  
PTH G20210A        
G allele 159 (82.8) 126 (65.6) < 0.001 Ref.
2.5 (1.6-4.1)
A allele 33 (17.2) 66 (34.4)  
MTHFR C677T        
C allele 181 (94.4) 171 (89.1) 0.069 Ref.
2.0 (0.95-4.3)
T allele 11 (5.6) 21 (10.9)  

Table 3: Genotypes and alleles distribution of the studied mutations in RSM patients and controls

PCR detection of FVL G169A mutation revealed that there was a significantly higher frequency of the AA genotype in the RSM group (24/96) when compared to controls (2/96), [P < 0.001, OR (95% CI) = 15.7 (3.6-68.5)]. In addition, A allele occurred more frequently in the patient group as compared with the control group [P=0.024, OR (95% CI) = 1.6 (1.06-2.4)].

Regarding the PTH G20210A mutation PCR results, there was a significantly higher frequency of the heterozygous GA genotype in patient group (60/96) than controls (31/96) [P < 0.0001, OR (95% CI) = 3.8 (2.05-6.9)]. Furthermore, minor allele (A) frequency was higher in the patient group than controls (P < 0.001, OR (95% CI) = 2.5 (1.6-4.1).

Finally, for the MTHFR C677T mutation, there was no significant difference in the distribution of genotypes [P = 0.056, OR (95% CI) =2.2 (0.98-4.8)] and alleles [P = 0.069, OR (95% CI) = 2.0 (0.95-4.3)] among RSM patients and controls.

Furthermore, analysis of the combined genotypes constructed by FVL, PTH and MTHFR mutations, revealed higher frequency of FVL AA, PTH GA, and MTHFR CC as well as FVL GA, PTH GA, and MTHFR CT in RSM patients than controls in the study population (Figure 2).

Factor-Leiden-combinations-patients

Figure 2. Frequency of genotype combinations in patients and controls. Combination of the three variants (1) FV G169A, (2) PTH G20210A, and (3) MTHFR C677T.

Figure 2. Frequency of genotype combinations in patients and controls. Combination of the three variants (1) FV G169A, (2) PTH G20210A, and (3) MTHFR C677T.

On employing association analysis between the frequencies of PTH G20210A and MTHFR C677T mutations and the available patients´ clinical and laboratory data, there were no considerable significant relations could be drawn (Table 4).

Characteristics PTH G20210A MTHFR C677T
GG GA+AA P value OR (95% CI) CC CT+TT P value OR (95% CI)
Total number 33 63     75 21    
Age                
≤35 y 30 (90.9) 57 (90.5) 0.944 1.0 69 (92.0) 18 (85.7) 0.389 1.0
>35 y 3 (9.1) 6 (9.5)   1.05 (0.25-4.50) 6 (8.0) 3 (14.3)   1.91 (0.44-8.4)
FH of abortion                
Negative 30 (90.9) 57 (90.5) 0.945 1.0 66 (88.0) 21 (100) 0.218 1.0
Positive 3 (9.1) 6 (9.5)   1.05 (0.25-4.50) 9 (12.0) 0 (0.0)   0.163 (0.0-2.9)
Obstetric history                
Duration of marriage 9.0 (3.0-11.0) 9.0 (5.0-11.0) 0.969   7.0 (3.0-10.5) 9.0 (5.0-13.0) 0.151  
No. of living children 1.0 (1.0-3.0) 1.0 (0.5-4.0) 0.639   1.0 (1.0-4.0) 4.0 (0.0-4.0) 0.359  
No. of abortions 3.0 (2.0-3.5) 5.0 (3.0-6.0) 0.031   3.0 (2.0-5.0) 3.0 (2.0-5.0) 0.762  
Medical disorder                
Negative 30 (90.9) 54 (85.7) 0.468 1.0 66 (88.0) 18 (85.7) 0.780 1.0
Positive 3 (9.1) 9 (14.3)   1.67 (0.42-6.63) 9 (12.0) 3 (14.3)   1.22 (0.30-5.0)
Drug history                
No drug intake 21 (63.6) 33 (52.4) 1.0 45 (60.0) 9 (42.9) 1.0
Aspirin 6 (18.2) 27 (42.9) 0.053 2.78 (0.98-7.85) 21 (28.0) 12 (57.1) 0.041 2.85 (1.04-7.83)
COCP 12 (36.4) 9 (14.3) 0.156 0.47 (0.17-1.33) 18 (24.0) 3 (14.3) 0.801 0.83 (0.20-3.44)
Clexane 12 (36.4) 6 (9.5) 0.050 0.32 (0.10-0.97) 12 (16.0) 6 (28.6) 0.139 2.5 (0.74-8.41)
Biochemical investigations                
PT 11 (10.6-11.9) 11 (10.5-11.7) 0.434   11 (10.5-11.8) 11.1 (10-11.8) 0.684  
INR 0.9 (0.92-1.07) 0.9 (0.90-1.0) 0.411   0.9 (0.92-1.05) 0.95 (0.9-1.06) 0.655  
PTT 31 (25.7-33.2) 30 (28.7-32.1) 0.667   30 (27.5-33.1) 31 (28.5-32.5) 0.765  

Table 4:Association of PTH G20210A and MTHFR C677T mutations with the clinical characteristics of RSM women

Discussion

Inherited thrombophilic mutations have been reported as one of the main causes of RSM. These mutations lead to disturbance of the trophoblast differentiation and placental vascularisation causing restrictions of the fetal growth, failure of pregnancy, placental insufficiency and therefore miscarriages (Incebiyik et al., 2014).

In the current study, the homo-mutant AA genotype of FVL and the heterozygous mutant GA genotype of PTH were significantly associated with RSM compared to the controls (P < 0.0001). These results support the relative high incidence of thrombophilic mutations in the Northern area of Saudi Arabia as reported in other areas of KSA in previous studies (Gawish and Al-Khamees, 2013; Saour et al., 2009; Gawish, 2015; Turki et al., 2016). In agreement with this finding, both mutations have been implicated as common genetic variants that predispose to early and/or late RSM in other populations as reported in Egyptian (Mohamed et al., 2010; Settin et al., 2011), Palestinian (Abu-Asab et al., 2011), Syrian (Mohammadi et al., 2007) and Turkish (Isaoglu et al., 2014) women.

The substitution of guanine to adenine at nucleotide 1691 in the exon 10 of factor V gene, leads to the single amino-acid replacement Arg506Gln which causes resistance to cleavage by the natural anticoagulant activated protein C and hence increased susceptibility to clotting (McNamee et al., 2012). The mutation in factor V Leiden is responsible for about 75% of inherited activated protein C resistance, which is the most common inherited thrombotic risk factor associated to repeated abortion (Mierla et al., 2012). On the other side, the replacement of adenine for guanine at position 20210 leading to hyper-prothrombinemia and subsequent an increase in thrombin generation. It has been also reported that carriers of PTH mutation have increased risk of venous thrombosis, arterial diseases and RSM 5-fold than normal (Jacobsen et al., 2010; Incebiyik et al., 2014; Fawzy et al., 2017). In addition, both of these mutations have been reported to be associated with other obstetric disorders such as abruptio placentae, intrauterine growth retardation or death (Turki et al., 2016). The findings of the previous studies and the current one could support the presumption that both FVL and PTH mutations are major risk factors for RSM. The actual mechanism by which inherited thrombophilia affecting recurrent pregnancy loss is still unknown. It has been suggested that thrombosis of maternal blood vessels may be related to the complications in association with thrombophilias (Mierla et al., 2012).

However, several studies did not report a significant association between these mutations and RSM (Kobashi et al., 2005; Altintas et al., 2007; Mierla et al., 2012; Poursadegh Zonouzi et al., 2013). This could be explained by the differences in ethnicity, the study sample size and design as well as the other interacting genetic and environmental factors that affect the final thrombophilic phenotype of the RSM patients (Almawi et al., 2005; Awad et al., 2013).

Regarding the MTHFR (C677T) mutation, our findings elucidated no significant difference in the frequency of this mutation between controls and patient group, and absence of homozygous mutant genotype in all study groups. This finding was in line with Gawish (2015), Turki et al. (2016), Isaoglu et al. (2014) as well as Osman and Abulata (2015) in Saudi, Turkish and Egyptian women. On contrast to our findings, others reported the association between this mutation and RSM (Jeddi-Tehrani et al., 2011). The MTHFR (C677T) mutation is involved in thrombophilia as the replacement of alanine by valine at codon 222 in the N-terminal of the protein resulting in decreased activity of MTHFR enzyme which leads to hyperhomocysteinemia which could predispose to thrombosis and RSM (Saour et al., 2009; Cao et al., 2013). Folic acid supplementation during conception as a general practice could be a reason of masking the effect of the MTHFR mutation in RSM patients as speculated by Turki et al. (2016) and Li et al. (2015).

Many studies showed that concomitant of two or more mutations have more unfavourable effects on pregnancy compared to the presence of a single hereditary thrombophilic factor (Coulam et al., 2006). This hypothesis is in agreement with our findings that showed a significant increase in specific combined mutation prevalence in RSM patients in comparison to normal controls. Multiple gene mutation concept as an RSM risk factor, has been reported previously (Coulam et al., 2006; Vora et al., 2008), but disagreed with others (Carp et al., 2002; Jaslow et al., 2010).

The role of thrombophilic gene variants in RSM has been speculated by many studies to be due to the presence of enhanced uncontrolled coagulation in the placental inter-villous spaces which in turn could induce deposition of fibrin within the fetal circulation, leading to multithrombotic events such as stem vessels thrombosis, infarction of the placenta, and spontaneous abortion (Osman and Abulata, 2015). Most of the results reported by different investigators for the same population showed inconsistency and this again may be due to the bias in patients’ selection and/or ethnic heterogeneity among the patients (Mohammadi et al., 2007). In addition, many authors suggest that methodological diversity, sample size and clinical heterogeneity may have a role in this discrepancy and contradiction.

Conclusion

The current study concludes that FVL and PTH gene mutations, but not MTHFR were significantly prevalent and associated with RSM in the study population. In addition, combined inheritance may have more accordance with the occurrence of thrombophilic events related to repeated abortions in the current area. An appropriate therapy for inherited and acquired thrombophilia will improve the pregnancy outcomes as recommended by De Santis et al. (2006). Furthermore, “a routine screening national medical program for these two genes in RSM patients in Saudi Arabia is highly recommended” (Turki et al., 2016).

We confirm that these preliminary findings will require further complementary studies that include other thrombogenic variants to help in planning a set of candidate genes which could be implicated in RSM of unknown aetiology in the study population.

Acknowledgments

The authors would like to thank all participants who agree to join this work.

Conflicts of interest

All authors declare they have no conflicts of interest

FUNDING SOURCE

This research was conducted at the Northern Border University, Arar, KSA and it was approved and supported by a grant from the Deanship of the Scientific Research in NBU; Grant of project No. (1-3-1436-5).

About the Authors

Corresponding Author

M. S. Fawzy

Department of Biochemistry, Faculty of Medicine, Northern Border University, Saudi Arabia

Email:
[email protected]

References

  • Abu-Asab NS, Ayesh SK, Ateeq RQ, Nasser SM, et al. (2011). Association of Inherited Thrombophilia with Recurrent Pregnancy Loss in Palestinian Women. Obstet Gynecol Int. 1-6.
  • Almawi WY, Keleshian SH, Borgi L, Fawaz NA, et al. (2005). Varied prevalence of factor V G1691A (Leiden) and prothrombin G20210A single nucleotide polymorphisms among Arabs. J Thromb Thrombolysis. 20: 163-168.
  • Altintas A, Pasa S, Akdeniz N, Cil T, et al. (2007). Factor V Leiden and G20210A prothrombin mutations in patients with recurrent pregnancy loss: data from the southeast of Turkey. Ann Hematol. 86: 727-731.
  • Awad NS, Almalki TA, Sabry AM, Mohamed AA, et al. (2013). Screening of Factor V G1691A (Leiden) and Factor II/prothrombin G20210A Polymorphisms among Apparently Healthy Taif-Saudi Arabia Population Using a Reverse Hybridization Strip Assay Approach. World J. Med. Sci. 9: 202-207.
  • Branch DW, Gibson M and Silver RM (2010). Recurrent miscarriage. New Engl. J. Med. 363: 1740-1747.
  • Cao Y, Xu J, Zhang Z, Huang X, et al. (2013). Association study between methylene-tetrahydrofolate reductase polymorphisms and unexplained recurrent pregnancy loss: a meta-analysis. Gene 514: 105-111.
  • Carp H, Dolitzky M, Tur-Kaspa I and Inbal A (2002). Hereditary thrombophilias are not associated with a decreased live birth rate in women with recurrent miscarriage. Fertil. Steril. 78:58-62.
  • ,  and  (2005). Recurrent miscarriage: pathophysiology and outcome. 17: 591-597.
  • Castoldi E1, Simioni P, Tormene D, Thomassen MC, et al. (2007). Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. J. Thromb. Haemost. 5:971-979.
  • Coulam CB, Jeyendran RS, Fishel LA, and Roussev R (2006). Multiple thrombophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage. Am. J. Reprod. Immunol. 55: 360-368.
  • De Santis M, Cavaliere AF, Straface G, Di Gianantonio E, et al. (2006). Inherited and acquired thrombophilia: pregnancy outcome and treatment. Reprod. Toxicol. 22: 227–233.
  • Fawzy MS, Toraih EA, Aly NM, Fakhr-Eldeen A, et al. (2017). Atherosclerotic and thrombotic genetic and environmental determinants in Egyptian coronary artery disease patients: a pilot study. BMC Cardiovascular Disorders 17:26.
  • Gawish G and Al-Khamees O (2013). Molecular Characterization of Factor V Leiden G1691A and Prothrombin G20210A Mutations in Saudi Females with Recurrent Pregnancy Loss. J. Blood Disord. Transf. 4: 165.
  • Gawish GE-H (2015). The Prevalence of Inherited Thrombophilic Polymorphisms in Saudi Females with Recurrent Pregnancy Loss Confirmed using Different Screening Protocols of PCR. J. Mol. Genet. Med. 9: 156.
  • Hossain N, Shamsi T, Khan N and Naz A (2013). Thrombophilia investigation in Pakistani women with recurrent pregnancy loss. J. Obstet. Gynaecol. Res. 39: 121-125.
  • Incebiyik A, Hilali NG, Camuzcuoglu A, Camuzcuoglu H et al. (2014). Prevalence of thromogenic gene mutations in women with recurrent miscarriage: A retrospective study of 1,507 patients. Obstet. Gynecol. Sci. 57: 513-517.
  • Isaoglu U, Ulug P, Delibas IB, Yilmaz M, et al. (2014). The association between inherited thrombophilia and recurrent pregnancy loss in Turkish women. Clin. Exp. Obstet. Gynecol. 41: 177-181.
  • Jacobsen AF, Dahm A, Bergrem A, Jacobsen EM, et al. (2010). Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms. J. Thromb. Haemostasis. 8: 2443-2449.
  • Jaslow CR, Carney JL and Kutteh WH (2010). Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil. Steril. 93:1234-1243.
  • Jeddi-Tehrani M, Torabi R, Zarnani AH, ,et al. (2011). Analysis of plasminogen activator inhibitor-1, integrin beta3, beta fibrinogen, and methylenetetrahydrofolate reductase polymorphisms in Iranian women with recurrent pregnancy loss. Am J Reprod Immunol. 66: 149–156.
  • Kasparová D and Fait T (2009). Early pregnancy loss and inherited thrombophilic states. Ceska. Gynekol. 74: 360-365.
  • Kobashi G, Kato EH, Morikawa M, Shimada S, et al. (2005). MTHFR C677T Polymorphism and Factor V Leiden Mutation Are Not Associated with Recurrent Spontaneous Abortion of Unexplained Etiology in Japanese Women. Semin. Thromb. Hemost. 31: 266-271.
  • Leclerc D, Sibani S and Rozen R (2000-2013). Molecular Biology of Methylenetetrahydrofolate Reductase (MTHFR) and Overview of Mutations/Polymorphisms. In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience.
  • Li X, Jiang J, Xu M, Xu M, et al. (2015). Individualized Supplementation of Folic Acid According to Polymorphisms of Methylenetetrahydrofolate Reductase (MTHFR), Methionine Synthase Reductase (MTRR) Reduced Pregnant Complications. Gynecol. Obstet. Invest. 79: 107–112.
  • Martínez-Zamora MÁ, Cervera R and Balasch J (2012). Recurrent miscarriage, antiphospholipid antibodies and the risk of thromboembolic disease. Clin. Rev. Allergy Immunol. 43: 265-274.
  • McNamee K, Dawood F and Farquharson RG (2012). Thrombophilia and early pregnancy loss. Best Pract. Res. Clin. Obstet. Gynaecol. 26: 91-102.
  • Mierla D, Szmal C, Neagos D, Cretu R, et al. (2012). Association of Prothrombin (A20210G) and Factor V Leiden (A506G) with Recurrent Pregnancy Loss. Maedica (Buchar) 7: 222-226.
  • Mohamed MA, El Moaty MA, El Kholy AF, Mohamed SA, et al. (2010).   Thrombophilic Gene Mutations in Women with Repeated Spontaneous Miscarriage. Genet. Test Mol. Biomarkers 14: 593-597.
  • Mohammadi MMA, Al-Halabi MG and Monem FMS (2007). Prevalence of factor V Leiden mutation and its relation with recurrent spontaneous pregnancy loss in a group of Syrian women. Middle East Fertil. Soc. J. 12: 179-183.
  • Osman O and Abulata N (2015). Inherited Thrombophilia and Early Recurrent Pregnancy Loss among Egyptian Women. Open J. Obstet. Gynecol. 5: 251-258.
  • Poursadegh Zonouzi A, Chaparzadeh N, Ghorbian S, Sadaghiani MM, et al. (2013). The association between thrombophilic gene mutations and recurrent pregnancy loss. J. Assist. Reprod. Genet. 30:1353-1359.
  • Saour JN, Shoukri MM and Mammo LA (2009). The Saudi Thrombosis and Familial Thrombophilia Registry. Design, rational, and preliminary results. Saudi Med. J. 30:1286–1290.
  • Settin A, Abo-Alkasema R, Ali E, ElBaz R, et al. (2011). Factor V Leiden and prothrombin gene mutations in Egyptian cases with unexplained recurrent pregnancy loss. Hematology 16: 59-63.
  • Teremmahi Ardestani M, Nodushan HH, Aflatoonian A, Ghasemi N, et al. (2013). Case control study of the factor V Leiden and factor II G20210A mutation frequency in women with recurrent pregnancy loss. Iran J. Reprod. Med. 11: 61-64.
  • Turki RF, Assidi M, Banni HA, Zahed HA, et al. (2016). Associations of recurrent miscarriages with chromosomal abnormalities, thrombophilia allelic polymorphisms and/or consanguinity in Saudi Arabia. BMC Med. Genet. 17:69.
  • Vora S, Shetty S and Ghosh K (2008). Thrombophilic dimension of recurrent fetal loss in Indian patients. Blood Coagul. Fibrinolysis 19: 581-584.
  • Yokus O (2010). Thrombophilic risk factors in women with recurrent abortion. J. Clin. Exp. Invest. 1: 168–172.

Keywords:
Download:
Full PDF